抗Omicron，有1方法救命！但用錯恐有嚴重致命風險？FDA再給輝瑞開綠燈！比變種病毒更可怕的是？美國住院率飆升，真的如此嗎？家用抗原檢測，10分鐘測出變種，防傳播、防重症！

🎯今日專家　林曉旭博士

🎯數據來源

輝瑞新冠口服藥

1.《科學》期刊：An oral SARS-CoV-2 Mproinhibitor clinical candidatefor the treatment of COVID-19

2. FDA：Coronavirus (COVID-19) Update: FDA Authorizes First Oral Antiviral for Treatment of COVID-19

3. 美國國家臨床試驗資料庫：STUDY OF PF-07321332 IN HEALTHY PARTICIPANTS

4. 美國國家臨床試驗資料庫：EPIC-HR: Study of Oral PF-07321332/Ritonavir Compared With Placebo in Nonhospitalized High Risk Adults With COVID-19

輝瑞新冠新藥和一些藥物服用，可能帶來生命危險

5. FDA說明書：FACT SHEET FOR HEALTHCARE PROVIDERS: EMERGENCY USE AUTHORIZATION FOR PAXLOVIDTM

默克新冠口服藥

6.FDA說明書：FACT SHEET FOR HEALTHCARE PROVIDERS: EMERGENCY USE AUTHORIZATION FOR MOLNUPIRAVIR

7.約翰·霍普金斯大學：WEEKLY HOSPITALIZATION TRENDS

美國住院率飆升？

8. CDC：COVID Data Tracker

家用新冠抗原檢測試劑

9. FDA：In Vitro Diagnostics EUAs – Antigen Diagnostic Tests for SARS-CoV-2

10.《國際傳染病學期刊》：Diagnostic accuracy of a SARS-CoV-2 rapid antigen test in real-life clinical settings

11. MedRxiv：Direct Comparison of SARS Co-V-2 Nasal RT- PCR and Rapid Antigen Test (BinaxNOW™) at a Community Testing Site During an Omicron Surge

12. 藥物交互作用查詢網站：Interactions with PAXLOVID (nirmatrelvir/ritonavir) and EVUSHELD (tixagevimab/cilgavimab) now available